SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Axogen, Inc. (AXGN) News

Follow Axogen, Inc. (AXGN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 32 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol AXGN Asset equity Sector Markets 90 days 28 Last 55.8 Updated Oct 29, 2026, 06:03 PM UTC Open live news feed Open AXGN chart & news
M Analysts Raise Price Targets for Axogen After Q3 Results Truist and Barclays lifted Axogen price targets to $60, from $53 and $50, respectively; Wells Fargo raised its target to $56 from $48. Truist and Barclays maintained Buy ratings. EQUITY | Oct 29, 2026, 06:03 PM UTC M AXGN Reports Fiscal Q3 Shareholder Net Loss AXGN reported a fiscal third-quarter net loss attributable to shareholders, down 636.79% year over year, and basic EPS was negative. EQUITY | Oct 29, 2026, 07:45 AM UTC M AxoGen shares surge after upbeat annual revenue outlook EQUITY | Oct 28, 2026, 03:39 PM UTC M AxoGen Reports Results for Quarter Ended September 30 EARNINGS | Oct 28, 2026, 02:09 PM UTC M Axogen Shares Rise 22% After Third-Quarter Revenue and Earnings Beat Expectations Axogen reported third-quarter revenue and earnings above analysts’ expectations. Its shares rose 22% to $45.61 in morning trading. EARNINGS | Oct 28, 2026, 02:04 PM UTC M Axogen Raises 2026 Revenue Guidance as Q3 Income and Revenue Increase Axogen shares rose more than 21% in early trading, according to MT Newswires. EQUITY | Oct 28, 2026, 01:36 PM UTC M Axogen Expects 2026 Revenue of at Least $290M in 2026 Axogen expects 2026 revenue of at least $290 million, versus a FactSet estimate of $283.8 million. EARNINGS | Oct 28, 2026, 11:22 AM UTC M Axogen Q3 Adjusted EPS $0.21 vs. IBES Estimate $0.14 Axogen reported Q3 adjusted EPS of $0.21, compared with the IBES estimate of $0.14. EARNINGS | Oct 28, 2026, 11:19 AM UTC M Axogen Q3 Net Income More Than Triples to $2.33 Million Q3 revenue rose 26% year over year to $75.83 million. EQUITY | Oct 28, 2026, 11:17 AM UTC M AxoGen Q3 Revenue Beats Estimates EQUITY | Oct 28, 2026, 11:13 AM UTC M Axogen Shares Rise 8.1% Premarket After Revenue Forecast Axogen shares rose 8.1% premarket after the company forecast full-year revenue above estimates. EARNINGS | Oct 28, 2026, 11:10 AM UTC M Axogen Sees 2026 Revenue at Least $290M EARNINGS | Oct 28, 2026, 11:07 AM UTC M AxoGen Q3 Revenue Reaches $75.8 Million AxoGen reported Q3 revenue of $75.8 million, compared with the IBES estimate of $73.2 million. EQUITY | Oct 28, 2026, 11:07 AM UTC M Axogen Reports Third-Quarter 2026 Financial Results EQUITY | Oct 28, 2026, 11:07 AM UTC M Axogen reports third-quarter adjusted EBITDA of $13.4 million EARNINGS | Oct 28, 2026, 11:07 AM UTC M Axogen Reports Q3 Gross Margin of 74.8% EARNINGS | Oct 28, 2026, 11:06 AM UTC M Axogen to report third-quarter 2026 results October 28 EQUITY | Oct 14, 2026, 11:00 AM UTC L Axogen Price Target Raised to $53.00/Share From $48.00 by Raymond James Ratings actions from Benzinga NEWS | Sep 25, 2026, 12:40 PM UTC H Axogen to acquire BioCircuit for $200 million in cash Axogen Inc. agreed to acquire BioCircuit Technologies Inc. for $200 million in cash, integrating NerveTape into its surgical solutions. To finance the purchase, it launched an underwritten public offering of 4.91 million MNA | Sep 10, 2026, 04:31 PM UTC L Axogen $200 million acquisition adds NerveTape to portfolio Axogen, Inc. is acquiring BioCircuit for $200 million, bringing NerveTape—a high-growth, FDA-approved nerve repair device—into the portfolio. The deal is expected to be accretive to revenue and EBITDA by 2027. EARNINGS | Sep 10, 2026, 01:18 PM UTC L AXGN to buy BioCircuit for $200 million cash acquisition AXGN will pay $200 million in cash to acquire BioCircuit, adding NerveTape and an FDA-approved suture-less nerve repair device to its portfolio. The deal is expected to be accretive to revenue and EBITDA by 2027. EARNINGS | Sep 10, 2026, 12:52 PM UTC L AXGN to buy an FDA-cleared sutureless nerve repair for $200M cash Axogen said it will acquire a differentiated, FDA-cleared sutureless nerve repair device. The $200M cash deal is expected to be accretive to revenue and margins in Year 1, with closing expected in Q4 2026. EARNINGS | Sep 10, 2026, 11:27 AM UTC H Axogen to buy BioCircuit Technologies for $200M in cash Axogen, NASDAQ:AXGN, has agreed to acquire privately held medical-device company BioCircuit Technologies for $200M in cash. The company plans to fund the purchase price with net proceeds from a concurrent public offer. MNA | Sep 10, 2026, 11:11 AM UTC L Axogen: Deal Adds NerveTape Device for Sutureless Peripheral Nerve Repair >AXGN Axogen: Deal Adds NerveTape Device for Sutureless Peripheral Nerve Repair >AXGN EQUITY | Sep 10, 2026, 10:16 AM UTC L Axogen enters definitive agreement to acquire BioCircuit Technologies Axogen Enters Into Definitive Agreement To Acquire BioCircuit Technologies >AXGN MNA | Sep 10, 2026, 10:04 AM UTC M Axogen prices $208.7 million public common stock offering EQUITY | Sep 10, 2026, 10:01 AM UTC L Axogen management to meet investors at Morgan Stanley healthcare conference Axogen said management will be available for one-on-one investor meetings at the 24th Annual Morgan Stanley Global Healthcare Conference. EQUITY | Sep 01, 2026, 11:08 AM UTC L Axogen to participate in Morgan Stanley Global Healthcare conference Axogen, Inc. will participate in the 24th Annual Morgan Stanley Global Healthcare Conference. EQUITY | Sep 01, 2026, 11:00 AM UTC L AXGN Axogen RESULTS: Q2, Q2 REV $69.7M vs. EST $67.1M, Q2 gross margin 72.7%, Q2 ADJ EBITDA $8.4M, Q2 ADJ Net Income $7.3M, Q2 Net Income $ AXGN Axogen RESULTS: Q2, Q2 REV $69.7M vs. EST $67.1M, Q2 gross margin 72.7%, Q2 ADJ EBITDA $8.4M, Q2 ADJ Net Income $7.3M, Q2 Net Income $-1.5M, Q2 ADJ EPS $0.12 vs. EST $0.12, Axogen Earnings Notes:, Outlook FY REV $27 EARNINGS | Jul 29, 2026, 11:07 AM UTC L AXGN - Axogen, Inc. Reports Second Quarter 2026 Financial Results AXGN - Axogen, Inc. Reports Second Quarter 2026 Financial Results EARNINGS | Jul 29, 2026, 11:05 AM UTC L serial disappointer risk (missed last 2 qtrs) in EPS reporters tonight and tomorrow morning - CAR, ASH, TLRY, PDM, BRSP, TRTX, PDS, TTAM, NO serial disappointer risk (missed last 2 qtrs) in EPS reporters tonight and tomorrow morning - CAR, ASH, TLRY, PDM, BRSP, TRTX, PDS, TTAM, NOV, MEOH, AAT, SW, AXGN EARNINGS | Jul 28, 2026, 04:09 PM UTC L STIM AXGN Neuronetics appoints nir naor Chief Financial Officer; announces additional management changes STIM AXGN Neuronetics appoints nir naor Chief Financial Officer; announces additional management changes EQUITY | Jul 20, 2026, 08:05 PM UTC